Nordicus Partners Corp (NORD): M&A transaction — Nordicus acquires remaining ~5% of Orocidin, making it wholly owned subsidiary

Nordicus Partners Corp

Acquired 29,663 Orocidin shares (5.34% of outstanding) for 200,000 restricted common shares.
Transaction closed November 12, 2024; Orocidin now 100% owned by Nordicus.
Orocidin is a clinical-stage biopharma developing periodontitis therapies.
Follows Nordicus' May 2024 purchase of 95% of Orocidin.

item 1.01 item 2.01 item 3.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Nordicus Partners Corp completed an acquisition involving shareholders of Orocidin A/S (closed 2024-11-12).

Action: acquisition
Counterparty: shareholders of Orocidin A/S
Closing: 2024-11-12

Exact text from the filing

on November 12, 2024, the Company acquired the Orocidin Shares pursuant to the Agreement.

View on SEC.gov

4 m&a transactions filed in the last 30 days. Browse all m&a transactions →

Nordicus Partners Corp filing history →

Source: SEC EDGAR

accession 0001493152-24-044999

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.